| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 01/03/2003 | CA2451602A1 Combination therapy of an sodm and a corticosteroid for prevention and/or treatment of inflammatory disease |
| 01/03/2003 | CA2451248A1 Composition comprising glycosaminoglycans and hyaluronidase inhibitors for the treatment of arthritic joints |
| 01/03/2003 | CA2451245A1 Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints |
| 01/03/2003 | CA2450969A1 Nucleic acid-associated proteins |
| 01/03/2003 | CA2450954A1 Method of treating atherosclerosis and other inflammatory diseases |
| 01/03/2003 | CA2450579A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450562A1 Tyrosine kinase inhibitors |
| 01/03/2003 | CA2450555A1 (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| 01/03/2003 | CA2450478A1 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | CA2450475A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2449844A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 01/02/2003 | US20030005470 Animal model for use in the diagnosis and treatment of tumors and bone matastasis |
| 01/02/2003 | US20030004324 31 human secreted proteins |
| 01/02/2003 | US20030004200 Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-YL] benzenesulfonamide |
| 01/02/2003 | US20030004196 Antiinflamamtory agents; autoimmune disease |
| 01/02/2003 | US20030004194 Method for treating fibrotic diseases or other indications VI |
| 01/02/2003 | US20030004193 Immunomodulators; antiinflammatory agents |
| 01/02/2003 | US20030004189 Pharmaceutical uses and synthesis of nicotinanilide-N-oxides |
| 01/02/2003 | US20030004185 Viricides, organ transplants, antiarthritic agents |
| 01/02/2003 | US20030004174 Antiinflammatory agents, anticancer agents, antihistamines, central nervous system disorders |
| 01/02/2003 | US20030004172 Cardiovascular disorders, osteoporosis, multiple sclerosis, antiarthritic agents |
| 01/02/2003 | US20030004165 Polyazanaphthalene compounds and pharmaceutical use thereof |
| 01/02/2003 | US20030004164 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004161 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004151 Cyclic derivatives as modulators of chemokine receptor activity |
| 01/02/2003 | US20030004146 Compositions for preventing hormone induced adverse effects |
| 01/02/2003 | US20030004144 Anticancer agents; skin disorders |
| 01/02/2003 | US20030004137 Muscle relaxants, controlling immunology, strokes, antidiabetic agents |
| 01/02/2003 | US20030004129 Formulations of adenosine a1 agonists |
| 01/02/2003 | US20030004110 Therapeutic compositions and methods for enhancing angiogenesis |
| 01/02/2003 | US20030004106 Interleukin-1 receptor antagonist-related molecules and uses thereof |
| 01/02/2003 | US20030003532 Novel nucleic acid sequences encoding human slit-, megf-, and roundabout-like polypeptides |
| 01/02/2003 | US20030003516 Therapeutic and diagnostic uses of antibody specificity profiles |
| 01/02/2003 | US20030003462 Novel human interleukin-like proteins and polynucleotides encoding them |
| 01/02/2003 | US20030003453 DNA molecule encoding a variant paraoxonase and uses thereof |
| 01/02/2003 | US20030003168 Enriched in at least two of the phytochemicals selected from the group consisting of isoflavones, lignans, saponins, catechins and phenolic acids. |
| 01/02/2003 | US20030003128 A prosthetic for dental implants comprising a polymeric base material(hydrogel) incorporating at least one active drug and base material releases active drug in a controlled manner when the prosthtic has been implanted in living organism |
| 01/02/2003 | EP1270577A1 Furoisoquinoline derivatives, process for producing the same and use thereof |
| 01/02/2003 | EP1270572A1 Condensed pyrazole derivatives, process for producing the same and use thereof |
| 01/02/2003 | EP1270570A1 Amide compounds and use thereof |
| 01/02/2003 | EP1270569A1 Substituted tryptophan derivatives |
| 01/02/2003 | EP1270044A2 Wound healing biomarkers |
| 01/02/2003 | EP1270015A2 A complex comprising OCIF and Polysaccharide |
| 01/02/2003 | EP1270001A1 Pharmaceutical composition containing calcium acetate and calcium carbonate |
| 01/02/2003 | EP1269998A1 Composition of prolonged liberation in the form of multiple granules that enables the maintenance of the therapeutic action of 4-nitro-2-phenoximethanesulfonanilide |
| 01/02/2003 | EP1269196A1 Method of screening for inhibitors of osteopontin |
| 01/02/2003 | EP1268820A2 Estrogen-regulated myo-inositol phosphate synthase: compositions and methods of use |
| 01/02/2003 | EP1268802A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 01/02/2003 | EP1268799A2 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability |
| 01/02/2003 | EP1268798A2 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 01/02/2003 | EP1268793A2 Fibroblast growth factor receptor-like molecules and uses thereof |
| 01/02/2003 | EP1268785A2 Gtp-binding protein gamma-12 subunit |
| 01/02/2003 | EP1268783A2 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 01/02/2003 | EP1268781A2 G12l, a gene associated with the thermal response |
| 01/02/2003 | EP1268778A1 Materials and methods relating to a novel splice variant of a na + dependent glutamate transporter |
| 01/02/2003 | EP1268775A1 The high bone mass gene of 11q13.3 |
| 01/02/2003 | EP1268773A1 Immune system-related polynucleotides, polypeptides, and antibodies |
| 01/02/2003 | EP1268554A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 01/02/2003 | EP1268549A2 Method of identifying inhibitors of tie-2 |
| 01/02/2003 | EP1268539A2 Estrogen-regulated unconventional myosin-related protein: compositions and methods of use |
| 01/02/2003 | EP1268537A1 Crystal structure of the (aml1 runt domain)/(cbfbeta) heterodimer and the ternary complex with dna |
| 01/02/2003 | EP1268489A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 01/02/2003 | EP1268487A1 Tricyclic protein kinase inhibitors |
| 01/02/2003 | EP1268486A2 Fused heterocyclic derivatives, their production and use |
| 01/02/2003 | EP1268481A2 Kinase inhibitors as therapeutic agents |
| 01/02/2003 | EP1268474A2 Substituted 1,3-thiazole compounds, their production and use |
| 01/02/2003 | EP1268471A1 N-heterocyclic derivatives as nos inhibitors |
| 01/02/2003 | EP1268465A1 Triarylimidazole derivatives as cytokine inhibitors |
| 01/02/2003 | EP1268455A2 Piperazine derivatives |
| 01/02/2003 | EP1268453A1 Estrogen agonist/antagonist metabolites |
| 01/02/2003 | EP1268445A1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |
| 01/02/2003 | EP1268444A1 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrmidines as antineoplastic agents |
| 01/02/2003 | EP1268437A1 Inhibitors of protein kinases |
| 01/02/2003 | EP1268431A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| 01/02/2003 | EP1268430A1 Chemical complex compprising a pyridine carboxy derivative and an h2 histamine receptor antagonist |
| 01/02/2003 | EP1268429A1 Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same |
| 01/02/2003 | EP1268425A2 Carbamate caspase inhibitors and uses thereof |
| 01/02/2003 | EP1268415A1 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds |
| 01/02/2003 | EP1268407A1 Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
| 01/02/2003 | EP1268404A1 Malonamic acids and derivatives thereof as thyroid receptor ligands |
| 01/02/2003 | EP1268389A2 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
| 01/02/2003 | EP1268387A2 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators |
| 01/02/2003 | EP1268096A1 Extrusion die |
| 01/02/2003 | EP1267931A1 Rhodamine derivatives for photodynamic diagnosis and treatment |
| 01/02/2003 | EP1267916A2 Medicament containing a tissue inhibitor of metalloproteinases-2 (timp-2) as an osteo-anabolically active substance |
| 01/02/2003 | EP1267915A2 Methods of treating diseases with activated protein c |
| 01/02/2003 | EP1267910A2 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
| 01/02/2003 | EP1267907A1 Use of mia in immunotherapy |
| 01/02/2003 | EP1267890A2 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity |
| 01/02/2003 | EP1267888A1 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification |
| 01/02/2003 | EP1267857A1 Method of inhibiting the expression of inflammatory cytokines and chemokines |
| 01/02/2003 | EP1267856A2 Treatment of icu-associated hypocalcemia with vitamin d compounds |
| 01/02/2003 | EP1267852A2 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
| 01/02/2003 | EP1267851A2 Method and compositions for preventing hormone induced adverse effects |
| 01/02/2003 | EP1267843A1 System for transporting active substances in a biological system |
| 01/02/2003 | EP1267839A2 Microspheres for active embolization |
| 01/02/2003 | EP1267806A2 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| 01/02/2003 | EP0980383B1 Pharmaceutically acceptable salts of 3-hydroxy-estr-5(10)-en-17-one 3-sulphate active as estrogens |
| 01/02/2003 | EP0980382B1 Estrogenic 19-norandrost-17-one derivatives with an aromatic b-ring |
| 01/02/2003 | EP0806960B1 Extracts of shark cartilage, process of production and uses thereof |